#USA #San Diego #Drug Discovery #PhenoVista Biosciences #Carolina Molecular

New Partnership Enhances Multi-omic Data Access

PhenoVista Biosciences, a leading contract research organization (CRO), and Carolina Molecular have announced a strategic partnership aimed at enhancing the accessibility of multi-omic data for their clients. This collaboration brings together the strengths of both organizations, combining PhenoVista's expertise in high-content imaging and assay services with Carolina Molecular's robust molecular testing capabilities.

The Importance of Multi-omic Data

In today's fast-paced biopharmaceutical landscape, having access to comprehensive data is crucial for effective drug discovery. Multi-omic data—integrating genomics, proteomics, and other omic technologies—enables scientists to gain deeper insights into the biological mechanisms underlying diseases. The collaboration between PhenoVista and Carolina Molecular is expected to empower researchers with a more holistic view of their drug candidates, significantly enhancing the decision-making process.

Leveraging Unique Expertise

PhenoVista is known for its advanced cell-based assay services, which specialize in high-content imaging and quantitative biology. By partnering with Carolina Molecular, PhenoVista aims to offer shared clients a combination of functional phenotypic data with molecular insights, thus providing a more comprehensive understanding of biological processes. Carolina Molecular brings over 20 years of experience in molecular testing, offering advanced immunoassay technologies and molecular profiling solutions, which are essential for gaining insights into protein markers and gene expression.

CEO Insights

James Evans, CEO and Co-Founder of PhenoVista, expressed his excitement about the partnership, stating, "As trends in the industry continue to shift towards increased outsourcing, a demand for more nuanced biological assays, and the necessity for complex datasets that can be coupled with machine learning, we are thrilled to be in a position to not only meet but exceed client expectations."

From Carolina Molecular's perspective, John L. Corliss, Co-Founder, shared his enthusiasm regarding the collaboration, remarking, "Carolina Molecular is thrilled to join forces with PhenoVista, combining our full-spectrum clinical and discovery expertise to deliver high-quality, data-driven solutions that push therapeutic innovation forward for both scientists and patients."

Enhanced Drug Discovery Experience

This partnership promises to provide clients with a robust platform from which to analyze and interpret their drug candidates comprehensively. By integrating Carolina Molecular's cutting-edge profiling technologies with PhenoVista's high-content imaging capabilities, researchers will be more equipped than ever to delve into the complexities of drug interactions, efficacy, and safety.

Increased collaboration within the life sciences sector points to a growing trend of leveraging specialized expertise to streamline processes and drive innovation. The combination of PhenoVista's imaging and analysis capabilities with Carolina Molecular's molecular testing services empowers scientists with access to high-quality, multi-omic data, paving the way for enhanced research and development efforts.

About PhenoVista Biosciences

PhenoVista is based in San Diego, California, and serves as a premier provider of imaging-based assay services. Their reputation is built on delivering high-quality data to biopharmaceutical clients of various sizes by employing cutting-edge cell models alongside advanced imaging technologies.

About Carolina Molecular

Carolina Molecular stands out as a leading molecular testing service laboratory, renowned for its commitment to high-quality testing over the past two decades. They offer a diverse array of services that meet all regulatory standards, ensuring flexibility and client-focused solutions in molecular testing.

The synergistic relationship between PhenoVista and Carolina Molecular signifies a monumental step towards evolving data accessibility in the field of drug discovery, promising innovative advancements that will benefit scientists and ultimately improve therapeutic outcomes for patients.